Distinct selective landscapes in mosquito and human cells shape dengue virus genetic diversity and highlight mechanisms of host adaptation in arboviruses.
The Dengue virus contains discretely folded RNA structures that confer the ability to resist a powerful host cell enzyme and produce a disease-inducing noncoding RNA.
Proteins produced by mast cells modulate the permeability of blood vessels, and may determine whether patients infected with dengue virus develop life-threatening complications.
Despite size heterogeneity, an epitope-resurfaced mature-form dengue VLP has the potential to induce quaternary structure-recognizing broad cross-reactive neutralizing antibodies.
Talaromyces (Tsp_PR) fungus render Aedes aegypti mosquitoes more susceptible to dengue virus infection through secreted molecules that impair midgut digestive enzyme transcription and activity.
Identification of viral and host determinants of broadly neutralizing antibodies targeting a new epitope on dengue virus that can be used to guide vaccine design.
In large vaccine trials conducted in dengue-endemic Asia and Latin America, the CYD-TDV tetravalent dengue vaccine shows limited variation in intra-serotype efficacy in the target population for vaccination (>9 years).
In vivo study of arbovirus infections reveals the dominant role of pDC IRF7-signaling in directing both type I and II IFN responses, and leading to viral control.
Investigation of antibody responses to variant Dengue virus proteins demonstrate new mechanisms that could increase the potential for vaccines to protect against mutable pathogens such as Flu, Dengue and HIV.
